Metagenomi Announces New Appointment to its Board of Directors
EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Eric Bjerkholt, MBA, CFO of Mirum Pharmaceuticals, Inc., will join Metagenomi’s Board of Directors, serving on Metagenomi’s Audit and Compensation committees, effective January 27, 2025.
“We are excited to welcome Eric to our Board of Directors,” said Brian C. Thomas, PhD, CEO and founder of Metagenomi. “His tremendous track record in the pharmaceutical industry as well as his experience in business development and capital formation will be an invaluable asset to Metagenomi as we continue to advance potentially curative treatment options for patients suffering from devastating disease.”
“I am thrilled to join Metagenomi at this important time of innovation and clinical validation in the broader gene editing space,” said Eric Bjerkholt, MBA, CFO of Mirum Pharmaceuticals. “I am excited to collaborate with the Board and the management team, which brings together some of the brightest innovators and industry veterans, to accelerate our development of precision genetic medicines.”
Mr. Bjerkholt brings extensive business leadership experience across a broad range of roles and is currently Chief Financial Officer of Mirum Pharmaceuticals, Inc. He joined Mirum from Chinook Therapeutics, Inc. where he also served as CFO overseeing financial reporting, planning and budgeting, internal controls, investor relations, facilities, and information technology functions. Chinook was acquired by Novartis AG. Prior to Chinook, Mr. Bjerkholt was CFO of Aimmune Therapeutics, which was acquired by Nestle Health Science. Previously Mr. Bjerkholt worked at Sunesis Pharmaceuticals, Inc., where in addition to CFO, he served in various capacities, including Executive Vice President of Corporate Development and Finance, Corporate Secretary and Chief Compliance Officer. Mr. Bjerkholt has also held senior executive finance roles at IntraBiotics Pharmaceuticals, Inc., LifeSpring Nutrition, Inc. and Age Wave, LLC and spent seven years in healthcare investment banking at J.P. Morgan & Company, Inc. Mr. Bjerkholt holds an MBA from Harvard Business School and a Cand.oecon. from the University of Oslo in Norway.